Toll Free: 1-888-928-9744

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Pipeline Review, H1 2016', provides in depth analysis on Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1)
- The report reviews Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Overview 6 Therapeutics Development 7 Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Products under Development by Stage of Development 7 Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Products under Development by Therapy Area 8 Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Products under Development by Indication 9 Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Products under Development by Companies 12 Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Companies Involved in Therapeutics Development 18 Basilea Pharmaceutica AG 18 Eli Lilly and Company 19 Millennium Pharmaceuticals, Inc. 20 Novartis AG 21 Redx Pharma Plc 22 Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Drug Profiles 23 BAL-3833 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 LXH-254 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 LY-3009120 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Inhibit Pan-Raf Kinases for Colorectal Cancer - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 TAK-580 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Dormant Projects 32 Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Featured News & Press Releases 33 Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting 33 Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting 33 Apr 22, 2015: Deciphera Pharmaceuticals Presents Data Highlighting pan-RAF inhibitor Cetuximab including Proprietary and Partnered Programs at AACR 2015 Annual Meeting 34 Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY3009120 at AACR Annual Meeting 2015 34 Apr 07, 2014: Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120 35 Sep 26, 2011: Sunesis Initiates Phase I Study Of MLN2480 In Advanced Solid Tumors 36 Jul 13, 2009: Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 36 Sep 07, 2004: Biogen Idec And Sunesis Form Collaboration To Discover And Develop Multiple Small Molecule Oncology Products 36 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 3
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 17 Pipeline by Basilea Pharmaceutica AG, H1 2016 18 Pipeline by Eli Lilly and Company, H1 2016 19 Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 20 Pipeline by Novartis AG, H1 2016 21 Pipeline by Redx Pharma Plc, H1 2016 22 Dormant Projects, H1 2016 32



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify